Article
Daily Medication Pearl: Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide)
Author(s):
Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.
Medication Pearl of the Day: Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide)
Indication: Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.
Insights:
- Dosing: One tablet taken once daily with food in patients who weigh at least 40 kg
- Dosage forms: Tablets: 800 mg of darunavir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide (equivalent to 11.2 mg of tenofovir alafenamide fumarate)
- Adverse events: The most common adverse reactions (all grades, incidence greater than or equal to 2%) were abdominal discomfort, diarrhea, fatigue, flatulence, headaches, nausea, and rash.
- Mechanism of action: Symtuza is a fixed-dose combination of antiretroviral drugs darunavir (plus the CYP3A inhibitor cobicistat), emtricitabine, and tenofovir alafenamide
- Manufacturer: Janssen Therapeutics
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
